News and Trends 2 Aug 2022 COUR NanoParticle technology halts Type 1 diabetes progression COUR Pharmaceuticals has published details of a study with the Miller Lab at Northwestern University, looking at type 1 diabetes. COUR develops novel immune-modifying nanoparticles (COUR NanoParticles or CNPs) designed to reprogram the immune system in treating autoimmune disorders. The data demonstrated durable tolerance using its novel platform technology in the non-obese diabetic (NOD) model […] August 2, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 SNIPR Biome announces new patent granted for applications targeting E. coli infections SNIPR Biome has today (August 2) announced that it has been granted a patent for medical applications supporting the company’s lead program – a bacteriophage cocktail targeting E.coli infections. Granted by the US Patent and Trademark Office (USPTO), the patent adds to its intellectual property portfolio that contains more than 20 granted patents in the […] August 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases A new drug discovery collaboration has taken place between Japanese Sosei Group Corporation and UK-based Abbvie with the hope of targeting neurological disease. This is the second partnership between the companies and offers the option to license agreement which is aimed at discovering, developing and commercializing small molecules that modulate novel G protein-coupled receptor (GPCR) […] August 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 Arecor Therapeutics adds diabetes product to portfolio after significant acquisition Arecor Therapeutics plc has bought all of Tetris Pharma Ltd shares adding a key commercial diabetes product to its portfolio. The company says as well as expanding its portfolio, the acquisition of the entire issued share capital complements its existing hospital products franchise and will speed up its revenue growth. Injectable products Tetris Pharma has […] August 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 FDA puts clinical hold on Beam Theraputics’ cancer therapy Beam Therapeutics Inc., a U.S. biotech company developing precision genetic medicines through base editing, says the company was informed via email last week that the U.S. Food and Drug Administration (FDA) has placed a hold on the BEAM-201 Investigational New Drug (IND) application for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T cell lymphoblastic […] August 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 Ipsen and Marengo Therapeutics partner to push immuno-oncology candidates into the clinic Ipsen and Marengo Therapeutics, Inc. have announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. Ipsen also announced it is exercising its option to acquire exclusive worldwide rights to an investigational ERK (extracellular signal-regulated kinase) inhibitor, discovered by AGV Discovery. Ipsen and Marengo Therapeutics details The collaboration between […] August 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 Immutep reports positive data from cancer study Immutep Limited, an Australian biotech company developing LAG-3-related immunotherapy treatments for cancer and autoimmune disease, has announced new interim data from second-line NSCLC (non-small cell lung cancer) patients (Part B) in its phase 2 TACTI-002 trial. The data was presented at the IASLC 2022 World Conference of Lung Cancer (WCLC 2022) in Vienna, Austria, and […] August 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 1 Aug 2022 The biggest US biotech investments in July 2022 The asthma specialist Areteia Therapeutics took the U.S.’ top private biotech investment crown in July 2022, with runners-up including liquid biopsy firm Delfi Diagnostics and the metabolic disease drug developer Carmot Therapeutics. The U.S.’ top private biotech investments in July 2022 didn’t reach the giddy heights of National Resilience’s $625 million Series D round in […] August 1, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 BioMed X Institute and Merck start new oncology research project BioMed X, a German independent research institute, has started a new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with the Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and trace back the mechanisms of […] August 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 Zenas BioPharma gets Chinese approval for thyroid eye disease treatment study Zenas BioPharma has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) of China to start a phase 1/2 clinical study of ZB001 to treat thyroid eye disease (TED). The main objective of the study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001. About […] August 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 Clinical hold on trial for colorectal cancer drug lifted by FDA A clinical hold has been lifted by the US Food and Drug Administration (FDA) on a trial for a treatment for colorectal cancer after changes were made by the company responsible. Belgium-based Celyad Oncology SA is a clinical biotech company focused on finding and developing chimeric antigen receptor T cell (CAR T) therapies for cancer. […] August 1, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 29 Jul 2022 Cancer patients enrolled on study to predict immunotherapy response An observational study has started enrolling patients with advanced/metastatic non-small cell lung cancer (NSCLC). Florida-based Nilogen Oncosystems made the announcement today (July 29) that those who are receiving immune checkpoint inhibitors in the standard of care will be registered for the study. Using advanced artificial intelligence and machine learning algorithms to discover biomarker signatures as […] July 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email